nodes	percent_of_prediction	percent_of_DWPC	metapath
Sunitinib—Protein Kinase Inhibitors—Vemurafenib—skin cancer	0.643	1	CiPCiCtD
Sunitinib—ABCG2—Vismodegib—skin cancer	0.0184	0.162	CbGbCtD
Sunitinib—ABCG2—Vemurafenib—skin cancer	0.0146	0.128	CbGbCtD
Sunitinib—ABCC4—Fluorouracil—skin cancer	0.0122	0.107	CbGbCtD
Sunitinib—ABCG2—Dactinomycin—skin cancer	0.00968	0.0851	CbGbCtD
Sunitinib—ABCB1—Vismodegib—skin cancer	0.00664	0.0584	CbGbCtD
Sunitinib—ABCG2—Fluorouracil—skin cancer	0.00654	0.0576	CbGbCtD
Sunitinib—CYP3A4—Imiquimod—skin cancer	0.00574	0.0505	CbGbCtD
Sunitinib—CYP3A4—Temozolomide—skin cancer	0.00574	0.0505	CbGbCtD
Sunitinib—ABCC2—Docetaxel—skin cancer	0.00553	0.0486	CbGbCtD
Sunitinib—ABCG2—Docetaxel—skin cancer	0.005	0.044	CbGbCtD
Sunitinib—CYP3A4—Vismodegib—skin cancer	0.00398	0.035	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Docetaxel—skin cancer	0.00369	0.0325	CbGbCtD
Sunitinib—CYP3A7—Docetaxel—skin cancer	0.00369	0.0325	CbGbCtD
Sunitinib—ABCB1—Dactinomycin—skin cancer	0.00349	0.0307	CbGbCtD
Sunitinib—CYP3A4—Vemurafenib—skin cancer	0.00315	0.0277	CbGbCtD
Sunitinib—CYP3A5—Docetaxel—skin cancer	0.00277	0.0244	CbGbCtD
Sunitinib—ABCB1—Docetaxel—skin cancer	0.0018	0.0159	CbGbCtD
Sunitinib—CYP3A4—Docetaxel—skin cancer	0.00108	0.0095	CbGbCtD
Sunitinib—RPS6KA1—Sorafenib—Vismodegib—skin cancer	0.00104	0.742	CbGdCrCtD
Sunitinib—Procainamide—SCN10A—skin cancer	0.000782	1	CrCbGaD
Sunitinib—CHEK2—Paclitaxel—Docetaxel—skin cancer	0.000362	0.258	CbGdCrCtD
Sunitinib—JAK2—skin of body—skin cancer	9.26e-05	0.0013	CbGeAlD
Sunitinib—CSNK1A1—female reproductive system—skin cancer	9.23e-05	0.00129	CbGeAlD
Sunitinib—MAP3K19—head—skin cancer	9.19e-05	0.00128	CbGeAlD
Sunitinib—CLK1—female reproductive system—skin cancer	9.17e-05	0.00128	CbGeAlD
Sunitinib—CLK4—lymph node—skin cancer	9.17e-05	0.00128	CbGeAlD
Sunitinib—IRAK1—mammalian vulva—skin cancer	9.16e-05	0.00128	CbGeAlD
Sunitinib—FYN—skin of body—skin cancer	9.13e-05	0.00128	CbGeAlD
Sunitinib—YES1—connective tissue—skin cancer	9.13e-05	0.00128	CbGeAlD
Sunitinib—PRKAA1—lymphoid tissue—skin cancer	9.11e-05	0.00127	CbGeAlD
Sunitinib—FLT1—epithelium—skin cancer	9.07e-05	0.00127	CbGeAlD
Sunitinib—ITK—lymph node—skin cancer	9.06e-05	0.00127	CbGeAlD
Sunitinib—SBK1—lymph node—skin cancer	9.06e-05	0.00127	CbGeAlD
Sunitinib—PTK2B—lymphoid tissue—skin cancer	9.01e-05	0.00126	CbGeAlD
Sunitinib—TAOK3—connective tissue—skin cancer	9.01e-05	0.00126	CbGeAlD
Sunitinib—DAPK3—head—skin cancer	9.01e-05	0.00126	CbGeAlD
Sunitinib—BMP2K—female reproductive system—skin cancer	9e-05	0.00126	CbGeAlD
Sunitinib—CAMK2G—female reproductive system—skin cancer	9e-05	0.00126	CbGeAlD
Sunitinib—RPS6KB1—mammalian vulva—skin cancer	8.99e-05	0.00126	CbGeAlD
Sunitinib—FLT4—lymphoid tissue—skin cancer	8.99e-05	0.00126	CbGeAlD
Sunitinib—PDGFRA—connective tissue—skin cancer	8.96e-05	0.00125	CbGeAlD
Sunitinib—BLK—lymph node—skin cancer	8.95e-05	0.00125	CbGeAlD
Sunitinib—FGR—mammalian vulva—skin cancer	8.94e-05	0.00125	CbGeAlD
Sunitinib—MAP3K3—skin of body—skin cancer	8.93e-05	0.00125	CbGeAlD
Sunitinib—CLK2—head—skin cancer	8.92e-05	0.00125	CbGeAlD
Sunitinib—LRRK2—female reproductive system—skin cancer	8.92e-05	0.00125	CbGeAlD
Sunitinib—AXL—mammalian vulva—skin cancer	8.9e-05	0.00124	CbGeAlD
Sunitinib—DAPK1—lymph node—skin cancer	8.85e-05	0.00124	CbGeAlD
Sunitinib—PHKG1—lymph node—skin cancer	8.85e-05	0.00124	CbGeAlD
Sunitinib—PRKAA1—female reproductive system—skin cancer	8.79e-05	0.00123	CbGeAlD
Sunitinib—STK3—head—skin cancer	8.76e-05	0.00123	CbGeAlD
Sunitinib—IRAK4—lymphoid tissue—skin cancer	8.73e-05	0.00122	CbGeAlD
Sunitinib—PTK2B—female reproductive system—skin cancer	8.69e-05	0.00122	CbGeAlD
Sunitinib—FLT4—female reproductive system—skin cancer	8.67e-05	0.00121	CbGeAlD
Sunitinib—ROCK1—head—skin cancer	8.65e-05	0.00121	CbGeAlD
Sunitinib—BRD4—lymph node—skin cancer	8.57e-05	0.0012	CbGeAlD
Sunitinib—STK11—lymph node—skin cancer	8.57e-05	0.0012	CbGeAlD
Sunitinib—SLK—mammalian vulva—skin cancer	8.57e-05	0.0012	CbGeAlD
Sunitinib—CSNK1E—female reproductive system—skin cancer	8.55e-05	0.0012	CbGeAlD
Sunitinib—MAP2K2—lymphoid tissue—skin cancer	8.53e-05	0.00119	CbGeAlD
Sunitinib—EPHB6—skin of body—skin cancer	8.53e-05	0.00119	CbGeAlD
Sunitinib—RIOK1—lymph node—skin cancer	8.49e-05	0.00119	CbGeAlD
Sunitinib—RPS6KA1—lymph node—skin cancer	8.49e-05	0.00119	CbGeAlD
Sunitinib—MAP3K2—lymphoid tissue—skin cancer	8.47e-05	0.00119	CbGeAlD
Sunitinib—JAK2—mammalian vulva—skin cancer	8.45e-05	0.00118	CbGeAlD
Sunitinib—DYRK1A—head—skin cancer	8.44e-05	0.00118	CbGeAlD
Sunitinib—FYN—mammalian vulva—skin cancer	8.33e-05	0.00117	CbGeAlD
Sunitinib—TNIK—lymph node—skin cancer	8.32e-05	0.00116	CbGeAlD
Sunitinib—MARK2—lymph node—skin cancer	8.32e-05	0.00116	CbGeAlD
Sunitinib—TBK1—lymphoid tissue—skin cancer	8.3e-05	0.00116	CbGeAlD
Sunitinib—SGK3—lymph node—skin cancer	8.25e-05	0.00115	CbGeAlD
Sunitinib—TYK2—lymphoid tissue—skin cancer	8.24e-05	0.00115	CbGeAlD
Sunitinib—MERTK—head—skin cancer	8.24e-05	0.00115	CbGeAlD
Sunitinib—ULK3—female reproductive system—skin cancer	8.23e-05	0.00115	CbGeAlD
Sunitinib—MAP2K2—female reproductive system—skin cancer	8.23e-05	0.00115	CbGeAlD
Sunitinib—MAP3K2—female reproductive system—skin cancer	8.17e-05	0.00114	CbGeAlD
Sunitinib—ICK—lymph node—skin cancer	8.17e-05	0.00114	CbGeAlD
Sunitinib—MAP4K5—mammalian vulva—skin cancer	8.14e-05	0.00114	CbGeAlD
Sunitinib—MAP3K3—mammalian vulva—skin cancer	8.14e-05	0.00114	CbGeAlD
Sunitinib—MAP4K4—head—skin cancer	8.09e-05	0.00113	CbGeAlD
Sunitinib—KDR—connective tissue—skin cancer	8.08e-05	0.00113	CbGeAlD
Sunitinib—TBK1—female reproductive system—skin cancer	8e-05	0.00112	CbGeAlD
Sunitinib—RPS6KB1—lymphoid tissue—skin cancer	7.98e-05	0.00112	CbGeAlD
Sunitinib—MAP3K12—head—skin cancer	7.97e-05	0.00112	CbGeAlD
Sunitinib—TYK2—female reproductive system—skin cancer	7.95e-05	0.00111	CbGeAlD
Sunitinib—RET—lymphoid tissue—skin cancer	7.93e-05	0.00111	CbGeAlD
Sunitinib—FGR—lymphoid tissue—skin cancer	7.93e-05	0.00111	CbGeAlD
Sunitinib—AXL—lymphoid tissue—skin cancer	7.9e-05	0.00111	CbGeAlD
Sunitinib—CHEK2—lymph node—skin cancer	7.89e-05	0.0011	CbGeAlD
Sunitinib—NUAK1—lymph node—skin cancer	7.89e-05	0.0011	CbGeAlD
Sunitinib—CSF1R—connective tissue—skin cancer	7.88e-05	0.0011	CbGeAlD
Sunitinib—FLT1—mammalian vulva—skin cancer	7.87e-05	0.0011	CbGeAlD
Sunitinib—RPS6KA3—head—skin cancer	7.86e-05	0.0011	CbGeAlD
Sunitinib—IRAK1—female reproductive system—skin cancer	7.85e-05	0.0011	CbGeAlD
Sunitinib—SNRK—lymph node—skin cancer	7.83e-05	0.00109	CbGeAlD
Sunitinib—OXSR1—lymph node—skin cancer	7.83e-05	0.00109	CbGeAlD
Sunitinib—INSR—lymph node—skin cancer	7.83e-05	0.00109	CbGeAlD
Sunitinib—MAP2K1—head—skin cancer	7.81e-05	0.00109	CbGeAlD
Sunitinib—EPHB6—mammalian vulva—skin cancer	7.78e-05	0.00109	CbGeAlD
Sunitinib—CSNK1A1—head—skin cancer	7.71e-05	0.00108	CbGeAlD
Sunitinib—STK38—lymph node—skin cancer	7.7e-05	0.00108	CbGeAlD
Sunitinib—RPS6KA2—lymph node—skin cancer	7.7e-05	0.00108	CbGeAlD
Sunitinib—RPS6KB1—female reproductive system—skin cancer	7.7e-05	0.00108	CbGeAlD
Sunitinib—KDR—epithelium—skin cancer	7.67e-05	0.00107	CbGeAlD
Sunitinib—CLK1—head—skin cancer	7.66e-05	0.00107	CbGeAlD
Sunitinib—FGR—female reproductive system—skin cancer	7.65e-05	0.00107	CbGeAlD
Sunitinib—AURKC—lymph node—skin cancer	7.64e-05	0.00107	CbGeAlD
Sunitinib—AXL—female reproductive system—skin cancer	7.62e-05	0.00107	CbGeAlD
Sunitinib—CSNK1G2—lymph node—skin cancer	7.58e-05	0.00106	CbGeAlD
Sunitinib—PKN1—lymph node—skin cancer	7.58e-05	0.00106	CbGeAlD
Sunitinib—BMP2K—head—skin cancer	7.52e-05	0.00105	CbGeAlD
Sunitinib—CAMK2G—head—skin cancer	7.52e-05	0.00105	CbGeAlD
Sunitinib—YES1—mammalian vulva—skin cancer	7.52e-05	0.00105	CbGeAlD
Sunitinib—JAK2—lymphoid tissue—skin cancer	7.5e-05	0.00105	CbGeAlD
Sunitinib—PRPF4—lymph node—skin cancer	7.47e-05	0.00105	CbGeAlD
Sunitinib—LRRK2—head—skin cancer	7.45e-05	0.00104	CbGeAlD
Sunitinib—STK10—mammalian vulva—skin cancer	7.45e-05	0.00104	CbGeAlD
Sunitinib—TAOK3—mammalian vulva—skin cancer	7.42e-05	0.00104	CbGeAlD
Sunitinib—FYN—lymphoid tissue—skin cancer	7.4e-05	0.00103	CbGeAlD
Sunitinib—PRPF4B—lymph node—skin cancer	7.37e-05	0.00103	CbGeAlD
Sunitinib—PRKAA1—head—skin cancer	7.34e-05	0.00103	CbGeAlD
Sunitinib—FGFR2—female reproductive system—skin cancer	7.27e-05	0.00102	CbGeAlD
Sunitinib—STK39—lymph node—skin cancer	7.27e-05	0.00102	CbGeAlD
Sunitinib—PTK2B—head—skin cancer	7.26e-05	0.00102	CbGeAlD
Sunitinib—FLT4—head—skin cancer	7.24e-05	0.00101	CbGeAlD
Sunitinib—JAK2—female reproductive system—skin cancer	7.23e-05	0.00101	CbGeAlD
Sunitinib—MAP4K5—lymphoid tissue—skin cancer	7.23e-05	0.00101	CbGeAlD
Sunitinib—CSNK2A1—lymph node—skin cancer	7.17e-05	0.001	CbGeAlD
Sunitinib—KIT—connective tissue—skin cancer	7.16e-05	0.001	CbGeAlD
Sunitinib—CSNK1E—head—skin cancer	7.14e-05	0.000999	CbGeAlD
Sunitinib—FYN—female reproductive system—skin cancer	7.13e-05	0.000998	CbGeAlD
Sunitinib—CSF1R—skin of body—skin cancer	7.12e-05	0.000996	CbGeAlD
Sunitinib—MYLK—lymph node—skin cancer	7.08e-05	0.00099	CbGeAlD
Sunitinib—IRAK4—head—skin cancer	7.03e-05	0.000984	CbGeAlD
Sunitinib—PDGFRB—connective tissue—skin cancer	6.99e-05	0.000978	CbGeAlD
Sunitinib—PLK4—lymph node—skin cancer	6.99e-05	0.000978	CbGeAlD
Sunitinib—FLT1—lymphoid tissue—skin cancer	6.99e-05	0.000977	CbGeAlD
Sunitinib—MAP4K5—female reproductive system—skin cancer	6.97e-05	0.000975	CbGeAlD
Sunitinib—MAP3K3—female reproductive system—skin cancer	6.97e-05	0.000975	CbGeAlD
Sunitinib—STK4—lymph node—skin cancer	6.95e-05	0.000972	CbGeAlD
Sunitinib—Urinary tract infection—Fluorouracil—skin cancer	6.95e-05	0.000823	CcSEcCtD
Sunitinib—Asthenia—Vemurafenib—skin cancer	6.94e-05	0.000823	CcSEcCtD
Sunitinib—Hypoaesthesia—Temozolomide—skin cancer	6.93e-05	0.000821	CcSEcCtD
Sunitinib—Chills—Dactinomycin—skin cancer	6.91e-05	0.000819	CcSEcCtD
Sunitinib—MAP2K2—head—skin cancer	6.88e-05	0.000962	CbGeAlD
Sunitinib—ULK3—head—skin cancer	6.88e-05	0.000962	CbGeAlD
Sunitinib—Urinary tract disorder—Temozolomide—skin cancer	6.88e-05	0.000815	CcSEcCtD
Sunitinib—Oedema peripheral—Temozolomide—skin cancer	6.86e-05	0.000813	CcSEcCtD
Sunitinib—Cardiac failure—Docetaxel—skin cancer	6.86e-05	0.000813	CcSEcCtD
Sunitinib—Pruritus—Vemurafenib—skin cancer	6.85e-05	0.000812	CcSEcCtD
Sunitinib—Connective tissue disorder—Temozolomide—skin cancer	6.84e-05	0.000811	CcSEcCtD
Sunitinib—MAP3K2—head—skin cancer	6.83e-05	0.000955	CbGeAlD
Sunitinib—Urethral disorder—Temozolomide—skin cancer	6.83e-05	0.000809	CcSEcCtD
Sunitinib—PHKG2—lymph node—skin cancer	6.82e-05	0.000954	CbGeAlD
Sunitinib—Alopecia—Dactinomycin—skin cancer	6.8e-05	0.000806	CcSEcCtD
Sunitinib—KIT—epithelium—skin cancer	6.8e-05	0.000951	CbGeAlD
Sunitinib—STK24—lymph node—skin cancer	6.79e-05	0.000949	CbGeAlD
Sunitinib—Gastrointestinal pain—Imiquimod—skin cancer	6.75e-05	0.0008	CcSEcCtD
Sunitinib—Epistaxis—Fluorouracil—skin cancer	6.74e-05	0.000799	CcSEcCtD
Sunitinib—FLT1—female reproductive system—skin cancer	6.74e-05	0.000943	CbGeAlD
Sunitinib—Hyponatraemia—Docetaxel—skin cancer	6.72e-05	0.000797	CcSEcCtD
Sunitinib—DAPK2—lymph node—skin cancer	6.71e-05	0.000938	CbGeAlD
Sunitinib—Erythema—Dactinomycin—skin cancer	6.7e-05	0.000794	CcSEcCtD
Sunitinib—Pain in extremity—Docetaxel—skin cancer	6.69e-05	0.000793	CcSEcCtD
Sunitinib—TBK1—head—skin cancer	6.69e-05	0.000935	CbGeAlD
Sunitinib—YES1—lymphoid tissue—skin cancer	6.67e-05	0.000934	CbGeAlD
Sunitinib—KDR—mammalian vulva—skin cancer	6.65e-05	0.00093	CbGeAlD
Sunitinib—MAP2K5—mammalian vulva—skin cancer	6.65e-05	0.00093	CbGeAlD
Sunitinib—TYK2—head—skin cancer	6.64e-05	0.000929	CbGeAlD
Sunitinib—Anaemia—Bleomycin—skin cancer	6.64e-05	0.000787	CcSEcCtD
Sunitinib—PDGFRB—epithelium—skin cancer	6.64e-05	0.000928	CbGeAlD
Sunitinib—Diarrhoea—Vemurafenib—skin cancer	6.62e-05	0.000785	CcSEcCtD
Sunitinib—STK10—lymphoid tissue—skin cancer	6.61e-05	0.000925	CbGeAlD
Sunitinib—STK16—lymph node—skin cancer	6.6e-05	0.000923	CbGeAlD
Sunitinib—TAOK3—lymphoid tissue—skin cancer	6.59e-05	0.000922	CbGeAlD
Sunitinib—Erythema multiforme—Temozolomide—skin cancer	6.58e-05	0.00078	CcSEcCtD
Sunitinib—HIPK2—lymph node—skin cancer	6.57e-05	0.000918	CbGeAlD
Sunitinib—HIPK3—lymph node—skin cancer	6.57e-05	0.000918	CbGeAlD
Sunitinib—ALK—lymph node—skin cancer	6.57e-05	0.000918	CbGeAlD
Sunitinib—PDGFRA—lymphoid tissue—skin cancer	6.55e-05	0.000916	CbGeAlD
Sunitinib—Body temperature increased—Imiquimod—skin cancer	6.53e-05	0.000774	CcSEcCtD
Sunitinib—Abdominal pain—Imiquimod—skin cancer	6.53e-05	0.000774	CcSEcCtD
Sunitinib—Eye disorder—Temozolomide—skin cancer	6.51e-05	0.000771	CcSEcCtD
Sunitinib—RIOK2—lymph node—skin cancer	6.5e-05	0.000909	CbGeAlD
Sunitinib—TNK1—lymph node—skin cancer	6.5e-05	0.000909	CbGeAlD
Sunitinib—CSF1R—mammalian vulva—skin cancer	6.49e-05	0.000908	CbGeAlD
Sunitinib—KIT—skin of body—skin cancer	6.46e-05	0.000904	CbGeAlD
Sunitinib—Cardiac disorder—Temozolomide—skin cancer	6.46e-05	0.000766	CcSEcCtD
Sunitinib—Flushing—Temozolomide—skin cancer	6.46e-05	0.000766	CcSEcCtD
Sunitinib—Haemoglobin—Fluorouracil—skin cancer	6.45e-05	0.000764	CcSEcCtD
Sunitinib—YES1—female reproductive system—skin cancer	6.44e-05	0.0009	CbGeAlD
Sunitinib—MAP4K1—lymph node—skin cancer	6.43e-05	0.0009	CbGeAlD
Sunitinib—RPS6KB1—head—skin cancer	6.43e-05	0.0009	CbGeAlD
Sunitinib—Leukopenia—Bleomycin—skin cancer	6.43e-05	0.000762	CcSEcCtD
Sunitinib—Haemorrhage—Fluorouracil—skin cancer	6.42e-05	0.000761	CcSEcCtD
Sunitinib—Dizziness—Vemurafenib—skin cancer	6.4e-05	0.000759	CcSEcCtD
Sunitinib—FGR—head—skin cancer	6.39e-05	0.000894	CbGeAlD
Sunitinib—RET—head—skin cancer	6.39e-05	0.000894	CbGeAlD
Sunitinib—Hypoaesthesia—Fluorouracil—skin cancer	6.38e-05	0.000757	CcSEcCtD
Sunitinib—STK10—female reproductive system—skin cancer	6.38e-05	0.000892	CbGeAlD
Sunitinib—AXL—head—skin cancer	6.37e-05	0.000891	CbGeAlD
Sunitinib—TAOK3—female reproductive system—skin cancer	6.36e-05	0.000889	CbGeAlD
Sunitinib—Angiopathy—Temozolomide—skin cancer	6.32e-05	0.000749	CcSEcCtD
Sunitinib—PDGFRA—female reproductive system—skin cancer	6.32e-05	0.000883	CbGeAlD
Sunitinib—PDGFRB—skin of body—skin cancer	6.31e-05	0.000883	CbGeAlD
Sunitinib—DAPK3—lymph node—skin cancer	6.31e-05	0.000882	CbGeAlD
Sunitinib—Immune system disorder—Temozolomide—skin cancer	6.29e-05	0.000746	CcSEcCtD
Sunitinib—Mediastinal disorder—Temozolomide—skin cancer	6.28e-05	0.000744	CcSEcCtD
Sunitinib—Cough—Bleomycin—skin cancer	6.27e-05	0.000743	CcSEcCtD
Sunitinib—CLK2—lymph node—skin cancer	6.25e-05	0.000874	CbGeAlD
Sunitinib—Chills—Temozolomide—skin cancer	6.25e-05	0.000741	CcSEcCtD
Sunitinib—KCNH2—nipple—skin cancer	6.23e-05	0.000871	CbGeAlD
Sunitinib—Dehydration—Docetaxel—skin cancer	6.22e-05	0.000738	CcSEcCtD
Sunitinib—MAP4K2—lymph node—skin cancer	6.22e-05	0.00087	CbGeAlD
Sunitinib—Anaemia—Dactinomycin—skin cancer	6.19e-05	0.000734	CcSEcCtD
Sunitinib—Liver function test abnormal—Docetaxel—skin cancer	6.18e-05	0.000733	CcSEcCtD
Sunitinib—Vomiting—Vemurafenib—skin cancer	6.15e-05	0.00073	CcSEcCtD
Sunitinib—Alopecia—Temozolomide—skin cancer	6.15e-05	0.000729	CcSEcCtD
Sunitinib—STK3—lymph node—skin cancer	6.14e-05	0.000858	CbGeAlD
Sunitinib—Dry skin—Docetaxel—skin cancer	6.14e-05	0.000727	CcSEcCtD
Sunitinib—Myalgia—Bleomycin—skin cancer	6.12e-05	0.000725	CcSEcCtD
Sunitinib—Chest pain—Bleomycin—skin cancer	6.12e-05	0.000725	CcSEcCtD
Sunitinib—Abdominal pain upper—Docetaxel—skin cancer	6.11e-05	0.000725	CcSEcCtD
Sunitinib—Rash—Vemurafenib—skin cancer	6.1e-05	0.000723	CcSEcCtD
Sunitinib—Mental disorder—Temozolomide—skin cancer	6.1e-05	0.000723	CcSEcCtD
Sunitinib—Dermatitis—Vemurafenib—skin cancer	6.1e-05	0.000723	CcSEcCtD
Sunitinib—Hypersensitivity—Imiquimod—skin cancer	6.08e-05	0.000721	CcSEcCtD
Sunitinib—FGFR2—head—skin cancer	6.07e-05	0.00085	CbGeAlD
Sunitinib—Headache—Vemurafenib—skin cancer	6.06e-05	0.000719	CcSEcCtD
Sunitinib—Malnutrition—Temozolomide—skin cancer	6.06e-05	0.000719	CcSEcCtD
Sunitinib—Erythema—Temozolomide—skin cancer	6.06e-05	0.000719	CcSEcCtD
Sunitinib—JAK2—head—skin cancer	6.04e-05	0.000845	CbGeAlD
Sunitinib—Toxic epidermal necrolysis—Docetaxel—skin cancer	6.03e-05	0.000715	CcSEcCtD
Sunitinib—Aspartate aminotransferase increased—Docetaxel—skin cancer	6.03e-05	0.000715	CcSEcCtD
Sunitinib—Leukopenia—Dactinomycin—skin cancer	6e-05	0.000711	CcSEcCtD
Sunitinib—Nasopharyngitis—Docetaxel—skin cancer	5.99e-05	0.00071	CcSEcCtD
Sunitinib—FYN—head—skin cancer	5.96e-05	0.000834	CbGeAlD
Sunitinib—Dysgeusia—Temozolomide—skin cancer	5.94e-05	0.000704	CcSEcCtD
Sunitinib—Asthenia—Imiquimod—skin cancer	5.92e-05	0.000702	CcSEcCtD
Sunitinib—KDR—lymphoid tissue—skin cancer	5.91e-05	0.000826	CbGeAlD
Sunitinib—DYRK1A—lymph node—skin cancer	5.91e-05	0.000826	CbGeAlD
Sunitinib—Alanine aminotransferase increased—Docetaxel—skin cancer	5.9e-05	0.0007	CcSEcCtD
Sunitinib—KIT—mammalian vulva—skin cancer	5.9e-05	0.000825	CbGeAlD
Sunitinib—Oedema—Bleomycin—skin cancer	5.86e-05	0.000695	CcSEcCtD
Sunitinib—Back pain—Temozolomide—skin cancer	5.86e-05	0.000695	CcSEcCtD
Sunitinib—Pruritus—Imiquimod—skin cancer	5.84e-05	0.000692	CcSEcCtD
Sunitinib—Infection—Bleomycin—skin cancer	5.83e-05	0.000691	CcSEcCtD
Sunitinib—MAP3K3—head—skin cancer	5.82e-05	0.000815	CbGeAlD
Sunitinib—MAP4K5—head—skin cancer	5.82e-05	0.000815	CbGeAlD
Sunitinib—Dysphagia—Docetaxel—skin cancer	5.78e-05	0.000686	CcSEcCtD
Sunitinib—MERTK—lymph node—skin cancer	5.77e-05	0.000807	CbGeAlD
Sunitinib—CSF1R—lymphoid tissue—skin cancer	5.76e-05	0.000806	CbGeAlD
Sunitinib—PDGFRB—mammalian vulva—skin cancer	5.76e-05	0.000805	CbGeAlD
Sunitinib—Nausea—Vemurafenib—skin cancer	5.75e-05	0.000682	CcSEcCtD
Sunitinib—Thrombocytopenia—Bleomycin—skin cancer	5.74e-05	0.000681	CcSEcCtD
Sunitinib—Arrhythmia—Fluorouracil—skin cancer	5.73e-05	0.000679	CcSEcCtD
Sunitinib—Myalgia—Dactinomycin—skin cancer	5.71e-05	0.000676	CcSEcCtD
Sunitinib—KDR—female reproductive system—skin cancer	5.7e-05	0.000797	CbGeAlD
Sunitinib—MAP2K5—female reproductive system—skin cancer	5.7e-05	0.000797	CbGeAlD
Sunitinib—Alopecia—Fluorouracil—skin cancer	5.67e-05	0.000672	CcSEcCtD
Sunitinib—MAP4K4—lymph node—skin cancer	5.66e-05	0.000792	CbGeAlD
Sunitinib—Diarrhoea—Imiquimod—skin cancer	5.65e-05	0.00067	CcSEcCtD
Sunitinib—FLT1—head—skin cancer	5.63e-05	0.000788	CbGeAlD
Sunitinib—NUAK2—lymph node—skin cancer	5.62e-05	0.000786	CbGeAlD
Sunitinib—Anaemia—Temozolomide—skin cancer	5.6e-05	0.000664	CcSEcCtD
Sunitinib—Anorexia—Bleomycin—skin cancer	5.59e-05	0.000663	CcSEcCtD
Sunitinib—Erythema—Fluorouracil—skin cancer	5.58e-05	0.000662	CcSEcCtD
Sunitinib—FLT3—lymph node—skin cancer	5.58e-05	0.000781	CbGeAlD
Sunitinib—MAP3K12—lymph node—skin cancer	5.58e-05	0.000781	CbGeAlD
Sunitinib—EPHB6—head—skin cancer	5.57e-05	0.000778	CbGeAlD
Sunitinib—CSF1R—female reproductive system—skin cancer	5.56e-05	0.000778	CbGeAlD
Sunitinib—Angioedema—Temozolomide—skin cancer	5.54e-05	0.000657	CcSEcCtD
Sunitinib—RPS6KA3—lymph node—skin cancer	5.51e-05	0.00077	CbGeAlD
Sunitinib—Pancytopenia—Docetaxel—skin cancer	5.49e-05	0.000651	CcSEcCtD
Sunitinib—MAP2K1—lymph node—skin cancer	5.47e-05	0.000765	CbGeAlD
Sunitinib—Oedema—Dactinomycin—skin cancer	5.47e-05	0.000648	CcSEcCtD
Sunitinib—Dizziness—Imiquimod—skin cancer	5.46e-05	0.000647	CcSEcCtD
Sunitinib—Infection—Dactinomycin—skin cancer	5.43e-05	0.000644	CcSEcCtD
Sunitinib—Leukopenia—Temozolomide—skin cancer	5.43e-05	0.000643	CcSEcCtD
Sunitinib—Neutropenia—Docetaxel—skin cancer	5.41e-05	0.000641	CcSEcCtD
Sunitinib—CSNK1A1—lymph node—skin cancer	5.4e-05	0.000755	CbGeAlD
Sunitinib—YES1—head—skin cancer	5.38e-05	0.000752	CbGeAlD
Sunitinib—CLK1—lymph node—skin cancer	5.36e-05	0.00075	CbGeAlD
Sunitinib—Thrombocytopenia—Dactinomycin—skin cancer	5.35e-05	0.000635	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Bleomycin—skin cancer	5.34e-05	0.000633	CcSEcCtD
Sunitinib—STK10—head—skin cancer	5.33e-05	0.000745	CbGeAlD
Sunitinib—TAOK3—head—skin cancer	5.31e-05	0.000743	CbGeAlD
Sunitinib—Cough—Temozolomide—skin cancer	5.29e-05	0.000627	CcSEcCtD
Sunitinib—PDGFRA—head—skin cancer	5.28e-05	0.000738	CbGeAlD
Sunitinib—Paraesthesia—Bleomycin—skin cancer	5.27e-05	0.000624	CcSEcCtD
Sunitinib—CAMK2G—lymph node—skin cancer	5.26e-05	0.000736	CbGeAlD
Sunitinib—BMP2K—lymph node—skin cancer	5.26e-05	0.000736	CbGeAlD
Sunitinib—Convulsion—Temozolomide—skin cancer	5.25e-05	0.000623	CcSEcCtD
Sunitinib—Vomiting—Imiquimod—skin cancer	5.25e-05	0.000622	CcSEcCtD
Sunitinib—KIT—lymphoid tissue—skin cancer	5.23e-05	0.000732	CbGeAlD
Sunitinib—Weight decreased—Docetaxel—skin cancer	5.23e-05	0.00062	CcSEcCtD
Sunitinib—Hypertension—Temozolomide—skin cancer	5.23e-05	0.00062	CcSEcCtD
Sunitinib—Dyspnoea—Bleomycin—skin cancer	5.23e-05	0.00062	CcSEcCtD
Sunitinib—LRRK2—lymph node—skin cancer	5.22e-05	0.00073	CbGeAlD
Sunitinib—Anorexia—Dactinomycin—skin cancer	5.21e-05	0.000618	CcSEcCtD
Sunitinib—Rash—Imiquimod—skin cancer	5.2e-05	0.000617	CcSEcCtD
Sunitinib—Dermatitis—Imiquimod—skin cancer	5.2e-05	0.000616	CcSEcCtD
Sunitinib—Pneumonia—Docetaxel—skin cancer	5.19e-05	0.000615	CcSEcCtD
Sunitinib—Headache—Imiquimod—skin cancer	5.17e-05	0.000613	CcSEcCtD
Sunitinib—Anaemia—Fluorouracil—skin cancer	5.16e-05	0.000612	CcSEcCtD
Sunitinib—Arthralgia—Temozolomide—skin cancer	5.16e-05	0.000612	CcSEcCtD
Sunitinib—Myalgia—Temozolomide—skin cancer	5.16e-05	0.000612	CcSEcCtD
Sunitinib—Infestation NOS—Docetaxel—skin cancer	5.16e-05	0.000611	CcSEcCtD
Sunitinib—Infestation—Docetaxel—skin cancer	5.16e-05	0.000611	CcSEcCtD
Sunitinib—PRKAA1—lymph node—skin cancer	5.14e-05	0.000719	CbGeAlD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	5.12e-05	0.000608	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Docetaxel—skin cancer	5.11e-05	0.000606	CcSEcCtD
Sunitinib—PDGFRB—lymphoid tissue—skin cancer	5.11e-05	0.000715	CbGeAlD
Sunitinib—Decreased appetite—Bleomycin—skin cancer	5.1e-05	0.000604	CcSEcCtD
Sunitinib—PTK2B—lymph node—skin cancer	5.08e-05	0.000711	CbGeAlD
Sunitinib—Acute coronary syndrome—Docetaxel—skin cancer	5.08e-05	0.000603	CcSEcCtD
Sunitinib—FLT4—lymph node—skin cancer	5.07e-05	0.000709	CbGeAlD
Sunitinib—Renal failure—Docetaxel—skin cancer	5.07e-05	0.000601	CcSEcCtD
Sunitinib—Neuropathy peripheral—Docetaxel—skin cancer	5.06e-05	0.000599	CcSEcCtD
Sunitinib—KIT—female reproductive system—skin cancer	5.05e-05	0.000706	CbGeAlD
Sunitinib—Dry mouth—Temozolomide—skin cancer	5.05e-05	0.000598	CcSEcCtD
Sunitinib—Stomatitis—Docetaxel—skin cancer	5.03e-05	0.000596	CcSEcCtD
Sunitinib—Pain—Bleomycin—skin cancer	5.01e-05	0.000594	CcSEcCtD
Sunitinib—CSNK1E—lymph node—skin cancer	5e-05	0.0007	CbGeAlD
Sunitinib—FGFR1—lymph node—skin cancer	5e-05	0.0007	CbGeAlD
Sunitinib—Leukopenia—Fluorouracil—skin cancer	5e-05	0.000593	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Dactinomycin—skin cancer	4.98e-05	0.000591	CcSEcCtD
Sunitinib—Oedema—Temozolomide—skin cancer	4.95e-05	0.000586	CcSEcCtD
Sunitinib—PDGFRB—female reproductive system—skin cancer	4.93e-05	0.00069	CbGeAlD
Sunitinib—IRAK4—lymph node—skin cancer	4.92e-05	0.000689	CbGeAlD
Sunitinib—Infection—Temozolomide—skin cancer	4.91e-05	0.000583	CcSEcCtD
Sunitinib—Nausea—Imiquimod—skin cancer	4.9e-05	0.000581	CcSEcCtD
Sunitinib—Hepatobiliary disease—Docetaxel—skin cancer	4.88e-05	0.000578	CcSEcCtD
Sunitinib—Epistaxis—Docetaxel—skin cancer	4.87e-05	0.000577	CcSEcCtD
Sunitinib—Nervous system disorder—Temozolomide—skin cancer	4.85e-05	0.000575	CcSEcCtD
Sunitinib—Thrombocytopenia—Temozolomide—skin cancer	4.84e-05	0.000574	CcSEcCtD
Sunitinib—Convulsion—Fluorouracil—skin cancer	4.84e-05	0.000574	CcSEcCtD
Sunitinib—ULK3—lymph node—skin cancer	4.82e-05	0.000673	CbGeAlD
Sunitinib—MAP2K2—lymph node—skin cancer	4.82e-05	0.000673	CbGeAlD
Sunitinib—Skin disorder—Temozolomide—skin cancer	4.8e-05	0.00057	CcSEcCtD
Sunitinib—MAP3K2—lymph node—skin cancer	4.78e-05	0.000669	CbGeAlD
Sunitinib—KDR—head—skin cancer	4.76e-05	0.000666	CbGeAlD
Sunitinib—MAP2K5—head—skin cancer	4.76e-05	0.000666	CbGeAlD
Sunitinib—Chest pain—Fluorouracil—skin cancer	4.75e-05	0.000564	CcSEcCtD
Sunitinib—Myalgia—Fluorouracil—skin cancer	4.75e-05	0.000564	CcSEcCtD
Sunitinib—Decreased appetite—Dactinomycin—skin cancer	4.75e-05	0.000564	CcSEcCtD
Sunitinib—MAP3K7—lymph node—skin cancer	4.74e-05	0.000662	CbGeAlD
Sunitinib—Fatigue—Dactinomycin—skin cancer	4.72e-05	0.000559	CcSEcCtD
Sunitinib—Anorexia—Temozolomide—skin cancer	4.72e-05	0.000559	CcSEcCtD
Sunitinib—TBK1—lymph node—skin cancer	4.68e-05	0.000655	CbGeAlD
Sunitinib—Pain—Dactinomycin—skin cancer	4.68e-05	0.000554	CcSEcCtD
Sunitinib—Haemoglobin—Docetaxel—skin cancer	4.65e-05	0.000552	CcSEcCtD
Sunitinib—TYK2—lymph node—skin cancer	4.65e-05	0.00065	CbGeAlD
Sunitinib—CSF1R—head—skin cancer	4.65e-05	0.00065	CbGeAlD
Sunitinib—Body temperature increased—Bleomycin—skin cancer	4.64e-05	0.00055	CcSEcCtD
Sunitinib—Hepatitis—Docetaxel—skin cancer	4.63e-05	0.000549	CcSEcCtD
Sunitinib—Haemorrhage—Docetaxel—skin cancer	4.63e-05	0.000549	CcSEcCtD
Sunitinib—Hypoaesthesia—Docetaxel—skin cancer	4.61e-05	0.000546	CcSEcCtD
Sunitinib—IRAK1—lymph node—skin cancer	4.59e-05	0.000642	CbGeAlD
Sunitinib—Urinary tract disorder—Docetaxel—skin cancer	4.57e-05	0.000542	CcSEcCtD
Sunitinib—Oedema peripheral—Docetaxel—skin cancer	4.56e-05	0.000541	CcSEcCtD
Sunitinib—Oedema—Fluorouracil—skin cancer	4.56e-05	0.00054	CcSEcCtD
Sunitinib—Connective tissue disorder—Docetaxel—skin cancer	4.55e-05	0.000539	CcSEcCtD
Sunitinib—Urethral disorder—Docetaxel—skin cancer	4.54e-05	0.000538	CcSEcCtD
Sunitinib—Infection—Fluorouracil—skin cancer	4.53e-05	0.000537	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Temozolomide—skin cancer	4.51e-05	0.000534	CcSEcCtD
Sunitinib—RPS6KB1—lymph node—skin cancer	4.5e-05	0.00063	CbGeAlD
Sunitinib—FGR—lymph node—skin cancer	4.48e-05	0.000626	CbGeAlD
Sunitinib—RET—lymph node—skin cancer	4.48e-05	0.000626	CbGeAlD
Sunitinib—Insomnia—Temozolomide—skin cancer	4.47e-05	0.00053	CcSEcCtD
Sunitinib—Gastrointestinal pain—Dactinomycin—skin cancer	4.47e-05	0.00053	CcSEcCtD
Sunitinib—Nervous system disorder—Fluorouracil—skin cancer	4.47e-05	0.00053	CcSEcCtD
Sunitinib—Thrombocytopenia—Fluorouracil—skin cancer	4.46e-05	0.000529	CcSEcCtD
Sunitinib—AXL—lymph node—skin cancer	4.46e-05	0.000624	CbGeAlD
Sunitinib—Paraesthesia—Temozolomide—skin cancer	4.44e-05	0.000527	CcSEcCtD
Sunitinib—Dyspnoea—Temozolomide—skin cancer	4.41e-05	0.000523	CcSEcCtD
Sunitinib—Erythema multiforme—Docetaxel—skin cancer	4.38e-05	0.000519	CcSEcCtD
Sunitinib—Dyspepsia—Temozolomide—skin cancer	4.35e-05	0.000516	CcSEcCtD
Sunitinib—Anorexia—Fluorouracil—skin cancer	4.34e-05	0.000515	CcSEcCtD
Sunitinib—Eye disorder—Docetaxel—skin cancer	4.33e-05	0.000513	CcSEcCtD
Sunitinib—Abdominal pain—Dactinomycin—skin cancer	4.32e-05	0.000513	CcSEcCtD
Sunitinib—Body temperature increased—Dactinomycin—skin cancer	4.32e-05	0.000513	CcSEcCtD
Sunitinib—Hypersensitivity—Bleomycin—skin cancer	4.32e-05	0.000512	CcSEcCtD
Sunitinib—Decreased appetite—Temozolomide—skin cancer	4.3e-05	0.00051	CcSEcCtD
Sunitinib—Flushing—Docetaxel—skin cancer	4.3e-05	0.000509	CcSEcCtD
Sunitinib—Cardiac disorder—Docetaxel—skin cancer	4.3e-05	0.000509	CcSEcCtD
Sunitinib—SLK—lymph node—skin cancer	4.29e-05	0.0006	CbGeAlD
Sunitinib—Gastrointestinal disorder—Temozolomide—skin cancer	4.27e-05	0.000506	CcSEcCtD
Sunitinib—Fatigue—Temozolomide—skin cancer	4.26e-05	0.000506	CcSEcCtD
Sunitinib—JAK2—lymph node—skin cancer	4.23e-05	0.000592	CbGeAlD
Sunitinib—Pain—Temozolomide—skin cancer	4.23e-05	0.000501	CcSEcCtD
Sunitinib—Constipation—Temozolomide—skin cancer	4.23e-05	0.000501	CcSEcCtD
Sunitinib—KIT—head—skin cancer	4.22e-05	0.00059	CbGeAlD
Sunitinib—Asthenia—Bleomycin—skin cancer	4.21e-05	0.000499	CcSEcCtD
Sunitinib—Angiopathy—Docetaxel—skin cancer	4.2e-05	0.000498	CcSEcCtD
Sunitinib—Immune system disorder—Docetaxel—skin cancer	4.18e-05	0.000496	CcSEcCtD
Sunitinib—Mediastinal disorder—Docetaxel—skin cancer	4.17e-05	0.000495	CcSEcCtD
Sunitinib—FYN—lymph node—skin cancer	4.17e-05	0.000584	CbGeAlD
Sunitinib—Chills—Docetaxel—skin cancer	4.15e-05	0.000493	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Fluorouracil—skin cancer	4.15e-05	0.000492	CcSEcCtD
Sunitinib—Pruritus—Bleomycin—skin cancer	4.15e-05	0.000492	CcSEcCtD
Sunitinib—Arrhythmia—Docetaxel—skin cancer	4.14e-05	0.00049	CcSEcCtD
Sunitinib—Insomnia—Fluorouracil—skin cancer	4.12e-05	0.000489	CcSEcCtD
Sunitinib—PDGFRB—head—skin cancer	4.12e-05	0.000576	CbGeAlD
Sunitinib—Paraesthesia—Fluorouracil—skin cancer	4.09e-05	0.000485	CcSEcCtD
Sunitinib—Alopecia—Docetaxel—skin cancer	4.09e-05	0.000485	CcSEcCtD
Sunitinib—MAP3K3—lymph node—skin cancer	4.08e-05	0.00057	CbGeAlD
Sunitinib—MAP4K5—lymph node—skin cancer	4.08e-05	0.00057	CbGeAlD
Sunitinib—Dyspnoea—Fluorouracil—skin cancer	4.06e-05	0.000482	CcSEcCtD
Sunitinib—Mental disorder—Docetaxel—skin cancer	4.06e-05	0.000481	CcSEcCtD
Sunitinib—Gastrointestinal pain—Temozolomide—skin cancer	4.05e-05	0.00048	CcSEcCtD
Sunitinib—Erythema—Docetaxel—skin cancer	4.03e-05	0.000478	CcSEcCtD
Sunitinib—Malnutrition—Docetaxel—skin cancer	4.03e-05	0.000478	CcSEcCtD
Sunitinib—Hypersensitivity—Dactinomycin—skin cancer	4.03e-05	0.000478	CcSEcCtD
Sunitinib—Dyspepsia—Fluorouracil—skin cancer	4.01e-05	0.000476	CcSEcCtD
Sunitinib—Decreased appetite—Fluorouracil—skin cancer	3.96e-05	0.00047	CcSEcCtD
Sunitinib—Dysgeusia—Docetaxel—skin cancer	3.95e-05	0.000468	CcSEcCtD
Sunitinib—FLT1—lymph node—skin cancer	3.94e-05	0.000551	CbGeAlD
Sunitinib—Gastrointestinal disorder—Fluorouracil—skin cancer	3.93e-05	0.000466	CcSEcCtD
Sunitinib—ABCC4—female reproductive system—skin cancer	3.93e-05	0.000549	CbGeAlD
Sunitinib—Asthenia—Dactinomycin—skin cancer	3.92e-05	0.000465	CcSEcCtD
Sunitinib—Abdominal pain—Temozolomide—skin cancer	3.91e-05	0.000464	CcSEcCtD
Sunitinib—Body temperature increased—Temozolomide—skin cancer	3.91e-05	0.000464	CcSEcCtD
Sunitinib—Back pain—Docetaxel—skin cancer	3.9e-05	0.000462	CcSEcCtD
Sunitinib—Pain—Fluorouracil—skin cancer	3.9e-05	0.000462	CcSEcCtD
Sunitinib—EPHB6—lymph node—skin cancer	3.9e-05	0.000545	CbGeAlD
Sunitinib—Muscle spasms—Docetaxel—skin cancer	3.88e-05	0.000459	CcSEcCtD
Sunitinib—ABCC2—female reproductive system—skin cancer	3.8e-05	0.000532	CbGeAlD
Sunitinib—ABCB1—blood vessel—skin cancer	3.78e-05	0.000529	CbGeAlD
Sunitinib—YES1—lymph node—skin cancer	3.77e-05	0.000527	CbGeAlD
Sunitinib—Diarrhoea—Dactinomycin—skin cancer	3.74e-05	0.000444	CcSEcCtD
Sunitinib—STK10—lymph node—skin cancer	3.73e-05	0.000522	CbGeAlD
Sunitinib—Vomiting—Bleomycin—skin cancer	3.73e-05	0.000442	CcSEcCtD
Sunitinib—Anaemia—Docetaxel—skin cancer	3.73e-05	0.000442	CcSEcCtD
Sunitinib—TAOK3—lymph node—skin cancer	3.72e-05	0.00052	CbGeAlD
Sunitinib—Rash—Bleomycin—skin cancer	3.7e-05	0.000438	CcSEcCtD
Sunitinib—PDGFRA—lymph node—skin cancer	3.69e-05	0.000517	CbGeAlD
Sunitinib—Dermatitis—Bleomycin—skin cancer	3.69e-05	0.000438	CcSEcCtD
Sunitinib—Hypersensitivity—Temozolomide—skin cancer	3.64e-05	0.000432	CcSEcCtD
Sunitinib—Leukopenia—Docetaxel—skin cancer	3.61e-05	0.000428	CcSEcCtD
Sunitinib—Body temperature increased—Fluorouracil—skin cancer	3.6e-05	0.000427	CcSEcCtD
Sunitinib—Asthenia—Temozolomide—skin cancer	3.55e-05	0.000421	CcSEcCtD
Sunitinib—Cough—Docetaxel—skin cancer	3.52e-05	0.000417	CcSEcCtD
Sunitinib—Pruritus—Temozolomide—skin cancer	3.5e-05	0.000415	CcSEcCtD
Sunitinib—Convulsion—Docetaxel—skin cancer	3.49e-05	0.000414	CcSEcCtD
Sunitinib—Nausea—Bleomycin—skin cancer	3.48e-05	0.000413	CcSEcCtD
Sunitinib—Hypertension—Docetaxel—skin cancer	3.48e-05	0.000413	CcSEcCtD
Sunitinib—Vomiting—Dactinomycin—skin cancer	3.48e-05	0.000412	CcSEcCtD
Sunitinib—Rash—Dactinomycin—skin cancer	3.45e-05	0.000409	CcSEcCtD
Sunitinib—Chest pain—Docetaxel—skin cancer	3.43e-05	0.000407	CcSEcCtD
Sunitinib—Myalgia—Docetaxel—skin cancer	3.43e-05	0.000407	CcSEcCtD
Sunitinib—Arthralgia—Docetaxel—skin cancer	3.43e-05	0.000407	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	3.41e-05	0.000404	CcSEcCtD
Sunitinib—Diarrhoea—Temozolomide—skin cancer	3.38e-05	0.000401	CcSEcCtD
Sunitinib—Hypersensitivity—Fluorouracil—skin cancer	3.36e-05	0.000398	CcSEcCtD
Sunitinib—Dry mouth—Docetaxel—skin cancer	3.36e-05	0.000398	CcSEcCtD
Sunitinib—KDR—lymph node—skin cancer	3.33e-05	0.000466	CbGeAlD
Sunitinib—MAP2K5—lymph node—skin cancer	3.33e-05	0.000466	CbGeAlD
Sunitinib—Oedema—Docetaxel—skin cancer	3.29e-05	0.00039	CcSEcCtD
Sunitinib—ABCC4—head—skin cancer	3.28e-05	0.000459	CbGeAlD
Sunitinib—Dizziness—Temozolomide—skin cancer	3.27e-05	0.000388	CcSEcCtD
Sunitinib—Infection—Docetaxel—skin cancer	3.27e-05	0.000387	CcSEcCtD
Sunitinib—CSF1R—lymph node—skin cancer	3.25e-05	0.000455	CbGeAlD
Sunitinib—Nausea—Dactinomycin—skin cancer	3.25e-05	0.000385	CcSEcCtD
Sunitinib—Shock—Docetaxel—skin cancer	3.24e-05	0.000384	CcSEcCtD
Sunitinib—ABCG2—mammalian vulva—skin cancer	3.24e-05	0.000453	CbGeAlD
Sunitinib—Nervous system disorder—Docetaxel—skin cancer	3.23e-05	0.000382	CcSEcCtD
Sunitinib—Pruritus—Fluorouracil—skin cancer	3.22e-05	0.000382	CcSEcCtD
Sunitinib—Thrombocytopenia—Docetaxel—skin cancer	3.22e-05	0.000382	CcSEcCtD
Sunitinib—Skin disorder—Docetaxel—skin cancer	3.2e-05	0.000379	CcSEcCtD
Sunitinib—Vomiting—Temozolomide—skin cancer	3.15e-05	0.000373	CcSEcCtD
Sunitinib—Anorexia—Docetaxel—skin cancer	3.14e-05	0.000372	CcSEcCtD
Sunitinib—Rash—Temozolomide—skin cancer	3.12e-05	0.00037	CcSEcCtD
Sunitinib—Diarrhoea—Fluorouracil—skin cancer	3.12e-05	0.00037	CcSEcCtD
Sunitinib—Dermatitis—Temozolomide—skin cancer	3.12e-05	0.000369	CcSEcCtD
Sunitinib—KCNH2—female reproductive system—skin cancer	3.12e-05	0.000436	CbGeAlD
Sunitinib—Headache—Temozolomide—skin cancer	3.1e-05	0.000367	CcSEcCtD
Sunitinib—Dizziness—Fluorouracil—skin cancer	3.01e-05	0.000357	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Docetaxel—skin cancer	3e-05	0.000355	CcSEcCtD
Sunitinib—Insomnia—Docetaxel—skin cancer	2.98e-05	0.000353	CcSEcCtD
Sunitinib—Paraesthesia—Docetaxel—skin cancer	2.95e-05	0.00035	CcSEcCtD
Sunitinib—KIT—lymph node—skin cancer	2.95e-05	0.000413	CbGeAlD
Sunitinib—Nausea—Temozolomide—skin cancer	2.94e-05	0.000348	CcSEcCtD
Sunitinib—Dyspnoea—Docetaxel—skin cancer	2.93e-05	0.000348	CcSEcCtD
Sunitinib—Vomiting—Fluorouracil—skin cancer	2.9e-05	0.000344	CcSEcCtD
Sunitinib—Dyspepsia—Docetaxel—skin cancer	2.9e-05	0.000343	CcSEcCtD
Sunitinib—PDGFRB—lymph node—skin cancer	2.88e-05	0.000403	CbGeAlD
Sunitinib—Rash—Fluorouracil—skin cancer	2.87e-05	0.000341	CcSEcCtD
Sunitinib—Dermatitis—Fluorouracil—skin cancer	2.87e-05	0.00034	CcSEcCtD
Sunitinib—Decreased appetite—Docetaxel—skin cancer	2.86e-05	0.000339	CcSEcCtD
Sunitinib—Headache—Fluorouracil—skin cancer	2.86e-05	0.000338	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Docetaxel—skin cancer	2.84e-05	0.000337	CcSEcCtD
Sunitinib—Fatigue—Docetaxel—skin cancer	2.84e-05	0.000336	CcSEcCtD
Sunitinib—Pain—Docetaxel—skin cancer	2.81e-05	0.000333	CcSEcCtD
Sunitinib—Constipation—Docetaxel—skin cancer	2.81e-05	0.000333	CcSEcCtD
Sunitinib—Nausea—Fluorouracil—skin cancer	2.71e-05	0.000321	CcSEcCtD
Sunitinib—Gastrointestinal pain—Docetaxel—skin cancer	2.69e-05	0.000319	CcSEcCtD
Sunitinib—KCNH2—head—skin cancer	2.6e-05	0.000364	CbGeAlD
Sunitinib—Abdominal pain—Docetaxel—skin cancer	2.6e-05	0.000308	CcSEcCtD
Sunitinib—Body temperature increased—Docetaxel—skin cancer	2.6e-05	0.000308	CcSEcCtD
Sunitinib—Hypersensitivity—Docetaxel—skin cancer	2.42e-05	0.000287	CcSEcCtD
Sunitinib—Asthenia—Docetaxel—skin cancer	2.36e-05	0.00028	CcSEcCtD
Sunitinib—Pruritus—Docetaxel—skin cancer	2.33e-05	0.000276	CcSEcCtD
Sunitinib—ABCC4—lymph node—skin cancer	2.3e-05	0.000321	CbGeAlD
Sunitinib—Diarrhoea—Docetaxel—skin cancer	2.25e-05	0.000267	CcSEcCtD
Sunitinib—ABCC2—lymph node—skin cancer	2.22e-05	0.000311	CbGeAlD
Sunitinib—Dizziness—Docetaxel—skin cancer	2.18e-05	0.000258	CcSEcCtD
Sunitinib—Vomiting—Docetaxel—skin cancer	2.09e-05	0.000248	CcSEcCtD
Sunitinib—Rash—Docetaxel—skin cancer	2.07e-05	0.000246	CcSEcCtD
Sunitinib—Dermatitis—Docetaxel—skin cancer	2.07e-05	0.000246	CcSEcCtD
Sunitinib—Headache—Docetaxel—skin cancer	2.06e-05	0.000244	CcSEcCtD
Sunitinib—Nausea—Docetaxel—skin cancer	1.95e-05	0.000232	CcSEcCtD
Sunitinib—CYP3A4—female reproductive system—skin cancer	1.93e-05	0.00027	CbGeAlD
Sunitinib—ABCB1—epithelium—skin cancer	1.84e-05	0.000257	CbGeAlD
Sunitinib—KCNH2—lymph node—skin cancer	1.82e-05	0.000255	CbGeAlD
Sunitinib—ABCG2—lymph node—skin cancer	1.62e-05	0.000227	CbGeAlD
Sunitinib—ABCB1—mammalian vulva—skin cancer	1.6e-05	0.000223	CbGeAlD
Sunitinib—ABCB1—lymphoid tissue—skin cancer	1.42e-05	0.000198	CbGeAlD
Sunitinib—ABCB1—female reproductive system—skin cancer	1.37e-05	0.000191	CbGeAlD
Sunitinib—ABCB1—head—skin cancer	1.14e-05	0.00016	CbGeAlD
Sunitinib—ABCB1—lymph node—skin cancer	8e-06	0.000112	CbGeAlD
Sunitinib—PDGFRB—Disease—PTGS2—skin cancer	1.3e-06	1.54e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—NRAS—skin cancer	1.3e-06	1.53e-05	CbGpPWpGaD
Sunitinib—KIT—Immune System—NRAS—skin cancer	1.29e-06	1.52e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—NRAS—skin cancer	1.29e-06	1.52e-05	CbGpPWpGaD
Sunitinib—PTK2B—Immune System—IL6—skin cancer	1.29e-06	1.52e-05	CbGpPWpGaD
Sunitinib—RPS6KA5—Signaling Pathways—IL6—skin cancer	1.28e-06	1.51e-05	CbGpPWpGaD
Sunitinib—FYN—Adaptive Immune System—HRAS—skin cancer	1.28e-06	1.51e-05	CbGpPWpGaD
Sunitinib—FYN—Innate Immune System—IL6—skin cancer	1.27e-06	1.5e-05	CbGpPWpGaD
Sunitinib—RPS6KA2—Signaling Pathways—IL6—skin cancer	1.27e-06	1.5e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Innate Immune System—IL6—skin cancer	1.27e-06	1.49e-05	CbGpPWpGaD
Sunitinib—JAK2—Innate Immune System—HRAS—skin cancer	1.26e-06	1.49e-05	CbGpPWpGaD
Sunitinib—CSNK1A1—Signaling Pathways—HRAS—skin cancer	1.26e-06	1.49e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—BRAF—skin cancer	1.26e-06	1.48e-05	CbGpPWpGaD
Sunitinib—FYN—Disease—PTGS2—skin cancer	1.26e-06	1.48e-05	CbGpPWpGaD
Sunitinib—BLK—Immune System—IL6—skin cancer	1.26e-06	1.48e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—BRAF—skin cancer	1.25e-06	1.48e-05	CbGpPWpGaD
Sunitinib—FGR—Immune System—IL6—skin cancer	1.25e-06	1.48e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling by GPCR—KRAS—skin cancer	1.25e-06	1.48e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—PTGS2—skin cancer	1.25e-06	1.47e-05	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—TP53—skin cancer	1.24e-06	1.47e-05	CbGpPWpGaD
Sunitinib—YES1—Immune System—KRAS—skin cancer	1.24e-06	1.46e-05	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—TP53—skin cancer	1.23e-06	1.46e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—NRAS—skin cancer	1.23e-06	1.45e-05	CbGpPWpGaD
Sunitinib—TYK2—Disease—NRAS—skin cancer	1.23e-06	1.45e-05	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—NRAS—skin cancer	1.22e-06	1.44e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—NRAS—skin cancer	1.22e-06	1.44e-05	CbGpPWpGaD
Sunitinib—FGFR2—Disease—NRAS—skin cancer	1.21e-06	1.43e-05	CbGpPWpGaD
Sunitinib—JAK2—Innate Immune System—IL6—skin cancer	1.21e-06	1.43e-05	CbGpPWpGaD
Sunitinib—CSNK1A1—Signaling Pathways—IL6—skin cancer	1.21e-06	1.43e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—KRAS—skin cancer	1.2e-06	1.42e-05	CbGpPWpGaD
Sunitinib—JAK2—Disease—PTGS2—skin cancer	1.19e-06	1.41e-05	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CSPG4—skin cancer	1.19e-06	1.41e-05	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—HRAS—skin cancer	1.19e-06	1.4e-05	CbGpPWpGaD
Sunitinib—KIT—Disease—NRAS—skin cancer	1.19e-06	1.4e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—NRAS—skin cancer	1.19e-06	1.4e-05	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—HRAS—skin cancer	1.18e-06	1.39e-05	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—KRAS—skin cancer	1.18e-06	1.39e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—BRAF—skin cancer	1.16e-06	1.37e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—NRAS—skin cancer	1.15e-06	1.36e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—NRAS—skin cancer	1.14e-06	1.35e-05	CbGpPWpGaD
Sunitinib—TYK2—Immune System—KRAS—skin cancer	1.14e-06	1.35e-05	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—IL6—skin cancer	1.14e-06	1.34e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—NRAS—skin cancer	1.14e-06	1.34e-05	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—IL6—skin cancer	1.13e-06	1.33e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—BRAF—skin cancer	1.13e-06	1.33e-05	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—KRAS—skin cancer	1.13e-06	1.33e-05	CbGpPWpGaD
Sunitinib—FGFR1—Disease—NRAS—skin cancer	1.13e-06	1.33e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—NRAS—skin cancer	1.13e-06	1.33e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—KRAS—skin cancer	1.13e-06	1.33e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—NRAS—skin cancer	1.13e-06	1.33e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—KRAS—skin cancer	1.12e-06	1.32e-05	CbGpPWpGaD
Sunitinib—KIT—Immune System—KRAS—skin cancer	1.11e-06	1.31e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—KRAS—skin cancer	1.11e-06	1.31e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—NRAS—skin cancer	1.1e-06	1.3e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—NRAS—skin cancer	1.1e-06	1.3e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—NRAS—skin cancer	1.1e-06	1.3e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—NRAS—skin cancer	1.1e-06	1.3e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—BRAF—skin cancer	1.09e-06	1.28e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—BRAF—skin cancer	1.08e-06	1.28e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—NRAS—skin cancer	1.07e-06	1.27e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—TP53—skin cancer	1.07e-06	1.26e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling by GPCR—HRAS—skin cancer	1.06e-06	1.25e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—KRAS—skin cancer	1.06e-06	1.25e-05	CbGpPWpGaD
Sunitinib—FYN—Immune System—NRAS—skin cancer	1.06e-06	1.25e-05	CbGpPWpGaD
Sunitinib—TYK2—Disease—KRAS—skin cancer	1.06e-06	1.24e-05	CbGpPWpGaD
Sunitinib—YES1—Immune System—HRAS—skin cancer	1.06e-06	1.24e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—NRAS—skin cancer	1.05e-06	1.24e-05	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—KRAS—skin cancer	1.05e-06	1.24e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—KRAS—skin cancer	1.05e-06	1.24e-05	CbGpPWpGaD
Sunitinib—FGFR2—Disease—KRAS—skin cancer	1.04e-06	1.23e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—NRAS—skin cancer	1.04e-06	1.23e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—BRAF—skin cancer	1.04e-06	1.22e-05	CbGpPWpGaD
Sunitinib—KIT—Disease—KRAS—skin cancer	1.02e-06	1.21e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—KRAS—skin cancer	1.02e-06	1.21e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—HRAS—skin cancer	1.02e-06	1.2e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling by GPCR—IL6—skin cancer	1.02e-06	1.2e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—NRAS—skin cancer	1.01e-06	1.2e-05	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—ERCC2—skin cancer	1.01e-06	1.2e-05	CbGpPWpGaD
Sunitinib—YES1—Immune System—IL6—skin cancer	1.01e-06	1.19e-05	CbGpPWpGaD
Sunitinib—JAK2—Immune System—NRAS—skin cancer	1.01e-06	1.19e-05	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—HRAS—skin cancer	1e-06	1.18e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—TP53—skin cancer	1e-06	1.18e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—KRAS—skin cancer	9.92e-07	1.17e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—TP53—skin cancer	9.91e-07	1.17e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—KRAS—skin cancer	9.84e-07	1.16e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—KRAS—skin cancer	9.78e-07	1.15e-05	CbGpPWpGaD
Sunitinib—FYN—Disease—NRAS—skin cancer	9.77e-07	1.15e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—IL6—skin cancer	9.76e-07	1.15e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—NRAS—skin cancer	9.72e-07	1.15e-05	CbGpPWpGaD
Sunitinib—TYK2—Immune System—HRAS—skin cancer	9.71e-07	1.15e-05	CbGpPWpGaD
Sunitinib—FGFR1—Disease—KRAS—skin cancer	9.71e-07	1.15e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—KRAS—skin cancer	9.69e-07	1.14e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—KRAS—skin cancer	9.69e-07	1.14e-05	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—HRAS—skin cancer	9.59e-07	1.13e-05	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—IL6—skin cancer	9.58e-07	1.13e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—HRAS—skin cancer	9.57e-07	1.13e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—KRAS—skin cancer	9.49e-07	1.12e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—KRAS—skin cancer	9.49e-07	1.12e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—HRAS—skin cancer	9.48e-07	1.12e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—KRAS—skin cancer	9.48e-07	1.12e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—KRAS—skin cancer	9.45e-07	1.12e-05	CbGpPWpGaD
Sunitinib—KIT—Immune System—HRAS—skin cancer	9.42e-07	1.11e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—HRAS—skin cancer	9.42e-07	1.11e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—NRAS—skin cancer	9.32e-07	1.1e-05	CbGpPWpGaD
Sunitinib—TYK2—Immune System—IL6—skin cancer	9.3e-07	1.1e-05	CbGpPWpGaD
Sunitinib—JAK2—Disease—NRAS—skin cancer	9.29e-07	1.1e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—KRAS—skin cancer	9.24e-07	1.09e-05	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—IL6—skin cancer	9.18e-07	1.08e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—IL6—skin cancer	9.16e-07	1.08e-05	CbGpPWpGaD
Sunitinib—FYN—Immune System—KRAS—skin cancer	9.11e-07	1.07e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—TP53—skin cancer	9.08e-07	1.07e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—IL6—skin cancer	9.08e-07	1.07e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—KRAS—skin cancer	9.06e-07	1.07e-05	CbGpPWpGaD
Sunitinib—KIT—Immune System—IL6—skin cancer	9.02e-07	1.06e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—IL6—skin cancer	9.02e-07	1.06e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—HRAS—skin cancer	9.01e-07	1.06e-05	CbGpPWpGaD
Sunitinib—TYK2—Disease—HRAS—skin cancer	8.97e-07	1.06e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—KRAS—skin cancer	8.94e-07	1.05e-05	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—HRAS—skin cancer	8.94e-07	1.05e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—HRAS—skin cancer	8.92e-07	1.05e-05	CbGpPWpGaD
Sunitinib—FGFR2—Disease—HRAS—skin cancer	8.86e-07	1.04e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—NRAS—skin cancer	8.84e-07	1.04e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—TP53—skin cancer	8.75e-07	1.03e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—KRAS—skin cancer	8.73e-07	1.03e-05	CbGpPWpGaD
Sunitinib—KIT—Disease—HRAS—skin cancer	8.7e-07	1.03e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—TP53—skin cancer	8.69e-07	1.03e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—HRAS—skin cancer	8.69e-07	1.02e-05	CbGpPWpGaD
Sunitinib—JAK2—Immune System—KRAS—skin cancer	8.66e-07	1.02e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—IL6—skin cancer	8.63e-07	1.02e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—NRAS—skin cancer	8.59e-07	1.01e-05	CbGpPWpGaD
Sunitinib—TYK2—Disease—IL6—skin cancer	8.58e-07	1.01e-05	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—IL6—skin cancer	8.56e-07	1.01e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—IL6—skin cancer	8.54e-07	1.01e-05	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PTGS2—skin cancer	8.49e-07	1e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—NRAS—skin cancer	8.48e-07	1e-05	CbGpPWpGaD
Sunitinib—FGFR2—Disease—IL6—skin cancer	8.48e-07	1e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—HRAS—skin cancer	8.43e-07	9.95e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—TP53—skin cancer	8.43e-07	9.94e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—TP53—skin cancer	8.43e-07	9.94e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—KRAS—skin cancer	8.41e-07	9.92e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PTGS2—skin cancer	8.41e-07	9.92e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—HRAS—skin cancer	8.37e-07	9.87e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—KRAS—skin cancer	8.37e-07	9.87e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—NRAS—skin cancer	8.33e-07	9.82e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—NRAS—skin cancer	8.33e-07	9.82e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—IL6—skin cancer	8.33e-07	9.82e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—IL6—skin cancer	8.32e-07	9.81e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—HRAS—skin cancer	8.31e-07	9.81e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—HRAS—skin cancer	8.26e-07	9.74e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—HRAS—skin cancer	8.24e-07	9.71e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—HRAS—skin cancer	8.23e-07	9.71e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—TP53—skin cancer	8.22e-07	9.69e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ENO2—skin cancer	8.12e-07	9.57e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—IL6—skin cancer	8.07e-07	9.52e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—HRAS—skin cancer	8.06e-07	9.51e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—HRAS—skin cancer	8.06e-07	9.51e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—HRAS—skin cancer	8.06e-07	9.5e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—HRAS—skin cancer	8.04e-07	9.48e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—KRAS—skin cancer	8.03e-07	9.47e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—IL6—skin cancer	8.01e-07	9.45e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—KRAS—skin cancer	8e-07	9.43e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—IL6—skin cancer	7.96e-07	9.39e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—NRAS—skin cancer	7.9e-07	9.32e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—IL6—skin cancer	7.9e-07	9.32e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—NRAS—skin cancer	7.88e-07	9.3e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—IL6—skin cancer	7.88e-07	9.3e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—IL6—skin cancer	7.88e-07	9.3e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—HRAS—skin cancer	7.86e-07	9.27e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—HRAS—skin cancer	7.75e-07	9.14e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—IL6—skin cancer	7.72e-07	9.1e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—IL6—skin cancer	7.72e-07	9.1e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—IL6—skin cancer	7.71e-07	9.1e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—HRAS—skin cancer	7.7e-07	9.09e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—IL6—skin cancer	7.69e-07	9.07e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—ERCC2—skin cancer	7.65e-07	9.02e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—KRAS—skin cancer	7.61e-07	8.98e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—HRAS—skin cancer	7.6e-07	8.97e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—IL6—skin cancer	7.52e-07	8.87e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—HRAS—skin cancer	7.42e-07	8.75e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—IL6—skin cancer	7.41e-07	8.74e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—KRAS—skin cancer	7.39e-07	8.72e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—IL6—skin cancer	7.37e-07	8.7e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—HRAS—skin cancer	7.36e-07	8.68e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—KRAS—skin cancer	7.3e-07	8.61e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—NRAS—skin cancer	7.28e-07	8.58e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—IL6—skin cancer	7.28e-07	8.58e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—KRAS—skin cancer	7.17e-07	8.45e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—KRAS—skin cancer	7.17e-07	8.45e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—HRAS—skin cancer	7.15e-07	8.43e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—TP53—skin cancer	7.13e-07	8.41e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—HRAS—skin cancer	7.11e-07	8.39e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—NRAS—skin cancer	7.1e-07	8.38e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—IL6—skin cancer	7.1e-07	8.38e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—IL6—skin cancer	7.05e-07	8.31e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—NRAS—skin cancer	6.85e-07	8.07e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—IL6—skin cancer	6.84e-07	8.07e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—HRAS—skin cancer	6.82e-07	8.05e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—NRAS—skin cancer	6.81e-07	8.03e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—IL6—skin cancer	6.81e-07	8.03e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—KRAS—skin cancer	6.8e-07	8.02e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—HRAS—skin cancer	6.8e-07	8.02e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—KRAS—skin cancer	6.78e-07	8e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—TP53—skin cancer	6.77e-07	7.98e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—TP53—skin cancer	6.57e-07	7.75e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—IL6—skin cancer	6.53e-07	7.7e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—NRAS—skin cancer	6.51e-07	7.67e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—IL6—skin cancer	6.51e-07	7.67e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TP53—skin cancer	6.49e-07	7.65e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—HRAS—skin cancer	6.47e-07	7.63e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TP53—skin cancer	6.37e-07	7.51e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TP53—skin cancer	6.37e-07	7.51e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—HRAS—skin cancer	6.28e-07	7.41e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—KRAS—skin cancer	6.26e-07	7.39e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—HRAS—skin cancer	6.2e-07	7.32e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—IL6—skin cancer	6.19e-07	7.3e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—KRAS—skin cancer	6.11e-07	7.21e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—HRAS—skin cancer	6.09e-07	7.19e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—HRAS—skin cancer	6.09e-07	7.19e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PTGS2—skin cancer	6.08e-07	7.17e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TP53—skin cancer	6.05e-07	7.13e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TP53—skin cancer	6.03e-07	7.11e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—IL6—skin cancer	6.01e-07	7.09e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—IL6—skin cancer	5.94e-07	7e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—KRAS—skin cancer	5.89e-07	6.95e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—KRAS—skin cancer	5.86e-07	6.91e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—IL6—skin cancer	5.83e-07	6.88e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—IL6—skin cancer	5.83e-07	6.88e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—HRAS—skin cancer	5.78e-07	6.82e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—HRAS—skin cancer	5.77e-07	6.8e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—KRAS—skin cancer	5.6e-07	6.61e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TP53—skin cancer	5.57e-07	6.57e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—IL6—skin cancer	5.53e-07	6.53e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—IL6—skin cancer	5.52e-07	6.51e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TP53—skin cancer	5.43e-07	6.41e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—HRAS—skin cancer	5.32e-07	6.28e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TP53—skin cancer	5.24e-07	6.18e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TP53—skin cancer	5.21e-07	6.14e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—HRAS—skin cancer	5.2e-07	6.13e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—IL6—skin cancer	5.1e-07	6.01e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—HRAS—skin cancer	5.01e-07	5.91e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—HRAS—skin cancer	4.98e-07	5.87e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TP53—skin cancer	4.98e-07	5.87e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—IL6—skin cancer	4.97e-07	5.86e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—IL6—skin cancer	4.79e-07	5.65e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—IL6—skin cancer	4.77e-07	5.62e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—HRAS—skin cancer	4.76e-07	5.61e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ERCC2—skin cancer	4.71e-07	5.56e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PTGS2—skin cancer	4.59e-07	5.41e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—IL6—skin cancer	4.56e-07	5.37e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PTGS2—skin cancer	2.83e-07	3.33e-06	CbGpPWpGaD
